Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Mar 24, 2026, 08:00 ET Optellum AI Shown to be Highly Cost-Effective in First US Lifetime Payer Study of Lung Nodule Risk Stratification
0721T and 0722T. [1] This yields an incremental cost-effectiveness ratio (ICER) of $4,485 per life-year gained (LYG), well below commonly used willingness-to-pay (WTP) thresholds of $100,000 per LYG. This marks the first study to show that an AI-assisted risk stratification of lung nodules can be highly cost-effective.Lung
More news about: Optellum